PT  - JOURNAL ARTICLE
AU  - Maria Karlgren
AU  - Ivailo Simoff
AU  - Markus Keiser
AU  - Stefan Oswald
AU  - Per Artursson
TI  - CRISPR-Cas9 - a new addition to the drug metabolism and disposition tool box
AID  - 10.1124/dmd.118.082842
DP  - 2018 Jan 01
TA  - Drug Metabolism and Disposition
PG  - dmd.118.082842
4099  - http://dmd.aspetjournals.org/content/early/2018/08/20/dmd.118.082842.short
4100  - http://dmd.aspetjournals.org/content/early/2018/08/20/dmd.118.082842.full
AB  - Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein 9 or CRISPR-Cas9 has been extensively used as a gene-editing technology during recent years. Unlike earlier technologies for gene-editing or gene knockdown, such as zinc finger nucleases and RNAi, CRISPR-Cas9 is comparably easy to use, affordable and versatile. Recently CRISPR-Cas9 has been applied in studies of drug absorption, disposition, metabolism and excretion (ADME) and for ADME model generation. Today about 50 papers have been published describing in vitro or in vivo CRISPR-Cas9 gene-editing of ADME and ADME-related genes. Twenty of these papers describe gene-editing of clinically relevant genes, such as ABC drug transporters and CYP drug metabolizing enzymes. With CRISPR-Cas9, the ADME tool box has been substantially expanded. This new technology allows us to develop better and more predictive in vitro and in vivo ADME models and map previously underexplored ADME genes and gene families. In this mini-review we give an overview of the CRISPR-Cas9 technology and summarize recent applications of CRISPR-Cas9 within the ADME field. We also speculate about future applications of CRISPR-Cas9 in ADME research.